[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Medical News & Perspectives
May 17, 2000

Tissue Engineering in the Genitourinary System

Author Affiliations

Not Available

Not Available

JAMA. 2000;283(19):2509. doi:10.1001/jama.283.19.2509-JMN0517-2-1

Boston—Evolving from dream to reality in only a few years, tissue engineering is beginning to provide clinical options in urology. This is quite an accomplishment, said Anthony Atala, MD, of Harvard Medical School, given that 10 years ago keeping urothelial cells alive in the laboratory for more than a few weeks was difficult.

Atala, who spoke at the American Society of Andrology meeting last month, has contributed much to the success of the field. It was at Harvard under his direction that the first urologic application of cell-based tissue engineering—the injection of autologous cells for the correction of vesicoureteral reflux in children—took place.

First Page Preview View Large
First page PDF preview
First page PDF preview